LATEST UPDATES » Vol 24, No. 09, September 2020 – 3D Technology: Additive Manufacturing Applications and Prospects       » Results of CD30 CAR-T Cell Therapy Trial Shows Promise for Hodgkin Lymphoma Patients       » Emerging Technologies and Innovations amid a Global Pandemic       » Monitoring COVID-19 Patients with AI-powered Platform       » Singapore Researchers Devise a Rapid COVID-19 Test Kit for the Detection of Neutralising Antibodies (NAbs) Against SARS-CoV-2       » Novel Ventilator Conceptualized by Singapore Clinicians Provides Efficient and Personalized Breathing Support for COVID-19 patients      
Vol 24, No. 08, August 2020   |   Issue PDF view/purchase
Proteomic Map of Human Lung Adenocarcinoma
Collaborative research from scientists across China have developed a comprehensive proteomic analysis on Chinese patients with lung adenocarcinoma (LUAD).

Lung cancer is one of the most commonly diagnosed and leading cause of cancer deaths in China. In past years, progress has been made in precision medicine and the genomic study of LUAD, however, many LUAD patients lack targeted therapeutic strategies.

This recent study demonstrated the molecular characteristics of LUAD, associated clinical outcomes, as well as potential prognostic biomarkers and drug targets. A comprehensive proteomic study of LUAD would be able to meet knowledge gaps between genomic abnormality and oncogenic protein function.

The team of scientists performed integrated proteomic and phosphoproteomic analyses of tumour tissues and their paired noncancerous adjacent tissues from 103 LUAD patients. A total of 11,119 proteins and 22,564 phosphorylation sites were identified. Combination of proteomics data with clinical information and genomics data produced an extensive molecular landscape of LUAD.

Through this research it was found that epithelial-mesenchymal transition, as well as inflammatory and oncogenic signalling pathways, likely led to poor prognosis in stage I LUAD. Links between genetic alterations and proteomic characteristics were determined in patients with EGFR or TP53 mutations.

Patients with EGFR mutation displayed increased expression of TTF-1 and Napsin-A. In contrast to patients with TP53 mutations, many oncogenic pathways including DNA replication and mismatch repair showed noticeable alteration.

Researchers categorised the patients into three proteomic subtypes (S-I, S-II, S-II), with each subtype showing different molecular and clinical characteristics. Comprehensive bioinformatic analysis showed that S-I patients were associated with a cellular environment and good prognosis. In contrast, S-III patients were associated with cell proliferation and proteome stability and a poor prognosis.

The phosphoproteomic analysis further revealed activated signalling pathways and kinases in different proteomic subtypes. The integrative analysis of proteomics data and clinical data further revealed 27 potential plasma biomarkers and several drug targets for LUAD.

With new insights on the genomics of LUAD, this proteomic dataset will provide valuable information and be an essential resource to boost the development of more precise diagnosis, prognosis and therapeutic options for LUAD patients.


news PharmaSources Launches the Export-Driven Event CPhI & P-MEC China E-Trade Season
news PharmaSources.com to Help Propel the Chinese API Export Business with E-Trade Session CPhI China Top API Exporters & Products
news Singapore Biomedical Company Appointed as a Certified Service Provider by 10x Genomics
news Proteona Honoured with "one to watch" Prize in the Inaugural Spinoff Prize by Nature Research and Merck Grou

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy